Development, Vol 127, Issue 7 1445-1453, Copyright © 2000 by Company of Biologists

JOURNAL ARTICLES

Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state

JJ Haigh, HP Gerber, N Ferrara and EF Wagner
Research Institute of Molecular Pathology (IMP), Dr Bohr-Gasse 7, A-1030 Vienna, Austria.

VEGF-A has been implicated in regulating the initial angiogenic invasion events that are essential for endochondral bone formation. VEGF-A mRNA expression was indeed found in the sclerotome of the developing somite and in the limb-bud mesenchyme at E10.5 in mouse development but declined during chondrogenesis and became upregulated in hypertrophic chondrocytes prior to angiogenic invasion. To determine the functional importance of VEGF-A expression in the developing chondrogenic tissues, VEGF-A was conditionally inactivated during early embryonic development using Collagen2a1-Cre transgenic lines. Deletion of a single VEGF-A allele in Collagen2a1-Cre-expressing cells results in embryonic lethality around E10.5. This lethality is characterized by aberrant development of the dorsal aorta and intersomitic blood vessels, along with defects in the developing endocardial and myocardial layers of the heart. A small percentage of VEGF(Flox)/+, Collagen2a1-Cre fetuses survive until E17.5, show aberrant endochondral bone formation and develop a heart phenotype resembling a dilated form of ischemic cardiomyopathy. These results provide insights into the function of VEGF-A in heart and endochondral bone formation and underscore the importance of tightly controlled levels of VEGF-A during development.

This article has been cited by other articles:

				Y. Mifune, T. Matsumoto, A. Kawamoto, R. Kuroda, T. Shoji, H. Iwasaki, S.-M. Kwon, M. Miwa, M. Kurosaka, and T. Asahara Local Delivery of Granulocyte Colony Stimulating Factor-Mobilized CD34-Positive Progenitor Cells Using Bioscaffold for Modality of Unhealing Bone Fracture Stem Cells, June 1, 2008; 26(6): 1395 - 1405. [Abstract] [Full Text] [PDF]

				J. Dai and A.B.M. Rabie VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification J. Dent. Res., October 1, 2007; 86(10): 937 - 950. [Abstract] [Full Text] [PDF]

				A. N. Athanasopoulos, D. Schneider, T. Keiper, V. Alt, U. R. Pendurthi, U. M. Liegibel, U. Sommer, P. P. Nawroth, C. Kasperk, and T. Chavakis Vascular Endothelial Growth Factor (VEGF)-induced Up-regulation of CCN1 in Osteoblasts Mediates Proangiogenic Activities in Endothelial Cells and Promotes Fracture Healing J. Biol. Chem., September 14, 2007; 282(37): 26746 - 26753. [Abstract] [Full Text] [PDF]

				S. H. L. George, M. Gertsenstein, K. Vintersten, E. Korets-Smith, J. Murphy, M. E. Stevens, J. J. Haigh, and A. Nagy Developmental and adult phenotyping directly from mutant embryonic stem cells PNAS, March 13, 2007; 104(11): 4455 - 4460. [Abstract] [Full Text] [PDF]

				E. Lepic, D. Burger, X. Lu, W. Song, and Q. Feng Lack of endothelial nitric oxide synthase decreases cardiomyocyte proliferation and delays cardiac maturation Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1240 - C1246. [Abstract] [Full Text] [PDF]

				K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel. Cancer Res., November 15, 2006; 66(22): 10919 - 10928. [Abstract] [Full Text] [PDF]

				Y. Chen, I. Amende, T. G. Hampton, Y. Yang, Q. Ke, J.-Y. Min, Y.-F. Xiao, and J. P. Morgan Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1653 - H1658. [Abstract] [Full Text] [PDF]

				S. R. Wedge, J. Kendrew, L. F. Hennequin, P. J. Valentine, S. T. Barry, S. R. Brave, N. R. Smith, N. H. James, M. Dukes, J. O. Curwen, et al. AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer Cancer Res., May 15, 2005; 65(10): 4389 - 4400. [Abstract] [Full Text] [PDF]

				T. Ara, K. Tokoyoda, R. Okamoto, P. A. Koni, and T. Nagasawa The role of CXCL12 in the organ-specific process of artery formation Blood, April 15, 2005; 105(8): 3155 - 3161. [Abstract] [Full Text] [PDF]

				G. Belteki, J. Haigh, N. Kabacs, K. Haigh, K. Sison, F. Costantini, J. Whitsett, S. E. Quaggin, and A. Nagy Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction Nucleic Acids Res., March 22, 2005; 33(5): e51 - e51. [Abstract] [Full Text] [PDF]

				F. Karreth, A. Hoebertz, H. Scheuch, R. Eferl, and E. F. Wagner The AP1 transcription factor Fra2 is required for efficient cartilage development Development, November 15, 2004; 131(22): 5717 - 5725. [Abstract] [Full Text] [PDF]

				N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]

				D. Pfander, T. Kobayashi, M. C. Knight, E. Zelzer, D. A. Chan, B. R. Olsen, A. J. Giaccia, R. S. Johnson, V. H. Haase, and E. Schipani Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development Development, May 15, 2004; 131(10): 2497 - 2508. [Abstract] [Full Text] [PDF]

				E. Zelzer, R. Mamluk, N. Ferrara, R. S. Johnson, E. Schipani, and B. R. Olsen VEGFA is necessary for chondrocyte survival during bone development Development, May 1, 2004; 131(9): 2161 - 2171. [Abstract] [Full Text] [PDF]

				J. J. Haigh, M. Ema, K. Haigh, M. Gertsenstein, P. Greer, J. Rossant, A. Nagy, and E. F. Wagner Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells Blood, February 1, 2004; 103(3): 912 - 920. [Abstract] [Full Text] [PDF]

				B. C. J. van der Eerden, M. Karperien, and J. M. Wit Systemic and Local Regulation of the Growth Plate Endocr. Rev., December 1, 2003; 24(6): 782 - 801. [Abstract] [Full Text] [PDF]

				A. J. Pantuck, G. Zeng, A. S. Belldegrun, and R. A. Figlin Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway Clin. Cancer Res., October 15, 2003; 9(13): 4641 - 4652. [Abstract] [Full Text] [PDF]

				J. C. Yang, L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer N. Engl. J. Med., July 31, 2003; 349(5): 427 - 434. [Abstract] [Full Text] [PDF]

				S. Ivkovic, B. S. Yoon, S. N. Popoff, F. F. Safadi, D. E. Libuda, R. C. Stephenson, A. Daluiski, and K. M. Lyons Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development Development, June 15, 2003; 130(12): 2779 - 2791. [Abstract] [Full Text] [PDF]

				M. Hirashima, M. Ogawa, S. Nishikawa, K. Matsumura, K. Kawasaki, M. Shibuya, and S.-I. Nishikawa A chemically defined culture of VEGFR2+ cells derived from embryonic stem cells reveals the role of VEGFR1 in tuning the threshold for VEGF in developing endothelial cells Blood, March 15, 2003; 101(6): 2261 - 2267. [Abstract] [Full Text] [PDF]

				E. Zelzer, W. McLean, Y.-S. Ng, N. Fukai, A. M. Reginato, S. Lovejoy, P. A. D'Amore, and B. R. Olsen Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis Development, March 6, 2003; 129(8): 1893 - 1904. [Abstract] [Full Text] [PDF]

				S. Childs, J.-N. Chen, D. M. Garrity, and M. C. Fishman Patterning of angiogenesis in the zebrafish embryo Development, March 4, 2003; 129(4): 973 - 982. [Abstract] [Full Text] [PDF]

				Y. Nakamichi, C. Shukunami, T. Yamada, K.-i. Aihara, H. Kawano, T. Sato, Y. Nishizaki, Y. Yamamoto, M. Shindo, K. Yoshimura, et al. Chondromodulin I Is a Bone Remodeling Factor Mol. Cell. Biol., January 15, 2003; 23(2): 636 - 644. [Abstract] [Full Text] [PDF]

				D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF]

				A. Behrens, J. Haigh, F. Mechta-Grigoriou, A. Nagy, M. Yaniv, and E. F. Wagner Impaired intervertebral disc formation in the absence of Jun Development, January 1, 2003; 130(1): 103 - 109. [Abstract] [Full Text] [PDF]

				N. Cheng, D. M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D. P. Cerretti, T. O. Daniel, and J. Chen Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis Mol. Cancer Res., November 1, 2002; 1(1): 2 - 11. [Abstract] [Full Text] [PDF]

				S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. A. Jackson, S. J. Boffey, P. J. Valentine, J. O. Curwen, H. L. Musgrove, et al. ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration Cancer Res., August 15, 2002; 62(16): 4645 - 4655. [Abstract] [Full Text] [PDF]

				E. Tham, J. Wang, F. Piehl, and G. Weber Upregulation of VEGF-A Without Angiogenesis in a Mouse Model of Dilated Cardiomyopathy Caused by Mitochondrial Dysfunction J. Histochem. Cytochem., July 1, 2002; 50(7): 935 - 944. [Abstract] [Full Text] [PDF]

				E. Schipani, H. E. Ryan, S. Didrickson, T. Kobayashi, M. Knight, and R. S. Johnson Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival Genes & Dev., November 1, 2001; 15(21): 2865 - 2876. [Abstract] [Full Text] [PDF]

				N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1358 - C1366. [Abstract] [Full Text] [PDF]

				D. S. Sohal, M. Nghiem, M. A. Crackower, S. A. Witt, T. R. Kimball, K. M. Tymitz, J. M. Penninger, and J. D. Molkentin Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein Circ. Res., July 6, 2001; 89(1): 20 - 25. [Abstract] [Full Text] [PDF]